12/20
02:03 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/19
08:07 am
blue
March Biosciences Elects Peter Olagunju as Chair of Board of Directors [Yahoo! Finance]
Low
Report
March Biosciences Elects Peter Olagunju as Chair of Board of Directors [Yahoo! Finance]
12/12
02:03 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/8
12:30 pm
blue
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Medium
Report
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
12/7
12:00 pm
blue
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Medium
Report
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
12/4
04:05 pm
blue
bluebird bio Announces 1-for-20 Reverse Stock Split
High
Report
bluebird bio Announces 1-for-20 Reverse Stock Split
12/4
08:47 am
blue
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
High
Report
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
12/4
02:08 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/26
03:06 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/18
03:07 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/15
01:19 pm
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
11/15
10:27 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $4.00 to $2.00. They now have an "overweight" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $4.00 to $2.00. They now have an "overweight" rating on the stock.
11/15
08:17 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
High
Report
bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
11/15
08:16 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $3.00.
High
Report
bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $3.00.
11/14
07:00 am
blue
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
Medium
Report
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
11/10
02:03 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/6
04:15 pm
blue
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
High
Report
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
11/5
09:05 am
blue
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Medium
Report
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
11/2
02:10 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/25
02:07 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/18
04:11 am
blue
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride [Seeking Alpha]
Low
Report
Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride [Seeking Alpha]
10/17
02:01 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/11
09:23 am
blue
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy [Yahoo! Finance]
Medium
Report
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy [Yahoo! Finance]
10/5
02:11 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/4
04:05 pm
blue
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)